Romanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
14 rezultate
Equine Rhinopneumonitis Virus
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
GENERAL DESCRIPTION OF INVENTION
The invention relates to a vaccine for the protection of Equidae against the effects of Equine Rhinopneumonitis, a method of preparation of the vaccine and to a method of protection of Equidae therewith.
Briefly stated, the invention comprises the steps of
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Compound WS 727713
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
TECHNICAL FIELD
The present invention relates to a new compound which is useful as a medicament or a cosmetic, to a process for producing the same and to a pharmaceutical composition comprising the same.
BACKGROUND ART
The melanocortin (MC) is a group of peptide hormones that are derived from
Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
TECHNICAL FIELD
The present invention is directed to certain isoxazolone compounds that inhibit the release of inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) from cells. The compounds of the invention, therefore, are useful in treating diseases involving unwanted
Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
TECHNICAL FIELD
The present invention is directed to certain isoxazolone compounds that inhibit the release of inflammatory cytokines such as interleukin-1 (1L-1) and tumor necrosis factor (TNF) from cells. The compounds of the invention, therefore, are useful in treating diseases involving unwanted
Inhibitors of glutaminyl cyclase
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF THE INVENTION
The invention relates to glutaminyl cyclase (QC, EC 2.3.2.5) that catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate
Inhibitors of glutaminyl cyclase
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
FIELD OF THE INVENTION
The invention relates to glutaminyl cyclase (QC, EC 2.3.2.5) that catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate
Inhibitors of glutaminyl cyclase
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
The Sequence Listing, which is a part of the present disclosure, includes a computer readable form and a written sequence listing comprising nucleotide and/or amino acid sequences of the present invention. The sequence listing information recorded in computer readable form is identical to the
Inhibitors of glutaminyl cyclase
Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
The Sequence Listing, which is a part of the present disclosure, includes a computer readable form and a written sequence listing comprising nucleotide and/or amino acid sequences of the present invention. The sequence listing information recorded in computer readable form is identical to the
Cea mai completă bază de date cu plante medicinale susținută de știință
- Funcționează în 55 de limbi
- Cure pe bază de plante susținute de știință
- Recunoașterea ierburilor după imagine
- Harta GPS interactivă - etichetați ierburile în locație (în curând)
- Citiți publicațiile științifice legate de căutarea dvs.
- Căutați plante medicinale după efectele lor
- Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele
Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate
